Search


 
Results 11 - 20 of about 91 for "FDA update".

Empagliflozin approved to treat type 2 diabetes | ACP ...

Empagliflozin (Jardiance), a sodium glucose co-transporter 2 inhibitor, was recently approved to treat type 2 diabetes in addition to diet and exercise ...

Saxagliptin under analysis for heart failure risk | ACP Diabetes ...

The FDA has requested clinical trial data on saxagliptin (Onglyza and Kombiglyze XR) to investigate a possible increase in heart failure in patients ...

New GLP-1 receptor agonist approved | ACP Diabetes ...

Albiglutide (Tanzeum), a glucagon-like peptide-1 (GLP-1) receptor agonist, was recently approved by the FDA to treat type 2 diabetes in adults, along ...

New warnings on medications containing saxagliptin ...

New warnings will be placed on saxagliptin and alogliptin about the potential risk of heart failure, particularly in patients with heart or kidney disease, ...

Warning on DPP-4 inhibitors and insulin recall | ACP Diabetes ...

Dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling, and some insulin pods may fail, the FDA recently warned ...

New GLP-1 agonist approved | ACP Diabetes Monthly

A new glucagon-like peptide-1 (GLP-1) receptor agonist, dulaglutide (Trulicity), was approved to treat type 2 diabetes, along with diet and exercise, the ...

SGLT2 inhibitors associated with ketoacidosis | ACP Diabetes ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, may cause ketoacidosis, the FDA recently ...

Glucose monitoring system approved specifically for critical ...

The FDA recently approved a new indication for the Nova StatStrip Glucose Hospital Meter System, extending its use to critically ill patients who have ...

New weight loss device approved | ACP Diabetes Monthly

A new balloon device (the ReShape Dual Balloon) was recently approved by the FDA to treat obesity without invasive surgery.

Warning on risks of canagliflozin | ACP Diabetes Monthly

The FDA on Sept. 10 released a strengthened warning on canagliflozin (Invokana, Invokamet) about increased risk of bone fractures and decreased ...

Result Page: < Previous  1 2 3 4 5 6  Next >